cetuximab preclinical antitumor activity monotherapy combination based predicted relative total activated epidermal growth facto pubmed ncbi abstract erbitux cetuximab proven therapeutic benefit clinical setting molecular determinants predicting responsiveness agent understood assessed relationship basal total activated py num epidermal growth factor receptor egfr levels tumor responsiveness cetuximab monotherapy combination-based treatment human xenograft models cetuximab treatment num num mg/mouse/injection num i p effectively delayed growth geo num tumors minimum num days log cell kill values num borderline activity num widr xenografts cetuximab failed show significant antitumor activity ht num hct num lovo colo num lx num hcc num num models studied tumors detectable variable levels egfr combination regimens cetuximab num mg/mouse/injection num num i p cisplatin num mg/kg/injection num num i v proved significantly efficacious individual monotherapies cisplatin-refractory cetuximab-responsive geo tumor model num therapeutic enhancement observed cisplatin cetuximab weakly responsive num xenograft similarly combinations cpt num mg/kg/injection num num i v cetuximab num mg/mouse/injection num num i p failed show improvements individual monotherapies cetuximab resistant/weakly responsive ht num num widr models conclude preclinical activity cetuximab monotherapy correlate directly relative basal levels total activated py num egfr tumor robust single-agent activity cetuximab predictor agent potentiate chemotherapy-mediated antitumor activities 
